Disease Activity and Tendency to Relapse in ANCA-Associated Vasculitis Are Reflected in Neutrophil and Intermediate Monocyte Frequencies

Figure 5

Increased monocyte frequencies in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients with rituximab treatment during the past 365 days. The frequencies of (a) total monocytes, (b) classical (CD14⁺⁺CD16⁻), (c) intermediate (CD14⁺⁺CD16⁺), and (d) nonclassical (CD14⁻CD16⁺) monocytes in patients with RTX or No RTX treatment. Total, classical, and intermediate monocytes were presented with higher frequency in patients in RTX treatment. No significant difference was observed in the comparison of nonclassical monocytes between the two groups. Mann–Whitney U test was used to calculate the level of significance. Data are presented with medians. Indicates p-value < 0.05. WBC, white blood cell; RTX, rituximab treatment; No RTX, no rituximab treatment; ns, not significant.

(a)

(b)

(c)

(d)